COMMUNIQUÉS West-GlobeNewswire

Antares Pharma Announces FDA Approval of Partner’s Product Utilizing Our QuickShot Auto Injector

15/02/2018 - 13:00

EWING, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS ) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals ( [...]

Merit Medical Closes Deal With BD for Purchase of Divestment Assets

15/02/2018 - 12:45

SOUTH JORDAN, Utah, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI ), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic [...]

Active Biotech announces rights issue of approximately SEK 48 million

15/02/2018 - 10:11

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD [...]

Zealand Pharma's dasiglucagon Phase 2a results at the 11th International Conference on ATTD

15/02/2018 - 09:09

Press release - No. 3/2018 Zealand Pharma's dasiglucagon Phase 2a results will be presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes Dasiglucagon was dosed using the [...]

NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING

15/02/2018 - 08:41

The shareholders of Active Biotech AB (publ) are invited to the Extraordinary Shareholders' Meeting to be held on Monday 19 March 2018, at 5 pm at the company's offices, Scheelevägen 22 in Lund, Sweden. ENTITLEMENT TO [...]

Active Biotech carries out rights issue

15/02/2018 - 08:31

Read the press release here Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/d7099433-338a-49f0-bf4b-5255146611fb

Active Biotech AB Year-end report January - December 2017

15/02/2018 - 08:31

Fourth quarter in brief The primary clinical endpoint was not met in the Phase II study (ARPEGGIO) with laquinimod in PPMS Patent regarding tasquinimod for the treatment of acute leukemia granted in Europe The process [...]

Dow BioMedica to distribute Biohit GastroPanel® in Korea

15/02/2018 - 08:30

Biohit Oyj Press release, 15 th February, 2018 at 9.30 a.m. local time (EET) Biohit Oyj and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea. The contract has been signed for [...]

Ossur Hf : Annual General Meeting 8 March 2018

15/02/2018 - 08:01

Announcement no. 10/2018 Reykjavik, 15 February 2018 Össur hf. - Annual General Meeting 8 March 2018 Össur hf.'s Annual General Meeting will be held on Thursday, 8 March 2018, at 9:00 am (GMT) at the Company's offices [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

15/02/2018 - 07:11

REGULATED INFORMATION GHENT, Belgium, 15 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

Navamedic ASA: Q4 2017 results

15/02/2018 - 07:02

Oslo, February 15, 2018 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 45.2 million in the fourth quarter of 2017, down from NOK 81.6 million in the same period in 2016, following the planned discontinuation of [...]

VALNEVA Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth

15/02/2018 - 07:01

Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of €109.8 million in 2017 (2016 - €97.9 million) representing year-on-year [...]

Valneva publie un très bon chiffre d'affaires 2017 soutenu par une croissance à deux chiffres des ventes de produits

15/02/2018 - 07:01

Valneva publie un très bon chiffre d'affaires 2017 soutenu par une croissance à deux chiffres des ventes de produits Forte croissance des ventes en 2017 (chiffres non audités) Chiffre d'affaires total de €109,8 millions [...]

Addex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors

15/02/2018 - 07:01

Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of [...]

Targovax ASA: Fourth quarter and full year 2017 results

15/02/2018 - 07:01

Oslo, Norway, 15 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its third quarter 2017 results. A meeting for [...]

Addex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors

15/02/2018 - 07:01

Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of [...]

MDxHealth Notice of Financial Year 2017 Results

15/02/2018 - 07:01

COMPANY ANNOUNCEMENT REGULATED INFORMATION INSIDE INFORMATION MDxHealth Notice of Financial Year 2017 Results Conference call for analysts and investors to be held on 22 February 2018 at 15:00 CET IRVINE, CA, and [...]

Avis de publication des résultats financiers de MDxHealth pour l'exercice 2017

15/02/2018 - 07:01

ANNONCE D'ENTREPRISE INFORMATIONREGLEMENTAIRE INFORMATION PRIVILEGIEE Avis de publication des résultats financiers de MDxHealth pour l'exercice 2017 Une conférence téléphonique pour les analystes et les investisseurs [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

15/02/2018 - 07:01

REGULATED INFORMATION GHENT, Belgium, 15 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]